Polio eradication, cessation of vaccination and re-emergence of disease

Nature Reviews Microbiology

Volumn 2, Issue 6, 2004, Pages 473-482

  Minor, Philip D ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; DIPHTHERIA VACCINE; DNA VACCINE; FOOT AND MOUTH DISEASE VACCINE; IMMUNOGLOBULIN; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; USOL D BAC;

AFGHANISTAN; CLINICAL TRIAL; DRUG COST; DRUG DESIGN; EGYPT; ENDEMIC DISEASE; EPIDEMIC; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; INDIA; INFECTION CONTROL; NIGERIA; NONHUMAN; PAKISTAN; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION; WILD TYPE; WORLD HEALTH ORGANIZATION; IMMUNOLOGY; METHODOLOGY; PREVENTIVE HEALTH SERVICE;

POLIOVIRUS;

HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLIOVIRUS VACCINES; VACCINES, ATTENUATED; WORLD HEALTH ORGANIZATION;

EID: 2942642293     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro906     Document Type: Review

References (46)

1. Aylward, R. B. et al. Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull. World Health Organ. 78, 285-297 (2000).
2. Hull, H. F., Ward, N. A., Hull, B. R., Milstien, J. B. & de Quadros, C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343, 1331-1337 (1994).
3. Nathanson N. & Martin, J. R. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity and disappearance. Am. J. Epidemiol. 110, 672-692 (1979).
4. Nkowane, B. U., Wassilak, S. G. & Orenstein, W. A. Vaccine-associated paralytic poliomyelitis in the United States: 1973 through 1984. JAMA 257, 1335-1340 (1987).
5. Andrus, J. K., Strebel, P. M., de Quadros, C. & Olive, J. M. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-1991. Bull. World Health Organ. 73, 33-40 (1995).
6. Strebel, P. M. et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus associated disease. Clin. Inf. Dis. 14, 568-579 (1992).
7. Kohler, K. A. et al. Compatible poliomyelitis cases in India during 2000. Bull. World Health Organ. 81, 2-9 (2003).
8. Joce, R., Wood, D., Brown, D. & Begg, N. Paralytic poliomyelitis in England and Wales 1985-1991. Brit. Med. Bull. 305, 79-87 (1992).
9. Kew, O. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296, 356-359 (2002).
10. Yang C.-F. et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J. Virol. 77, 8366-8377 (2003).
11. Kew, O. M. et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. World Health Organ. 82, 16-23 (2004).
12. Stanway, G. et al. Taxonomy of the picornaviridae: species designation and three new genera. [online] http://www.iah.bbsrc.ac.uk/primary_index/current_research/virus/ Picornaviridae/Europic/Europic2000/Posters/Stanway_et_al.pdf (European Study Group on the Molecular Biology of Picornaviruses, Italy, 2000).
13. Shulman, L. M. et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral polio vaccine strain isolated from sewage in Israel. J. Clin Microbiol. 38, 3729-3734 (2000).
14. Cherkasova, E. et al. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl Acad. Sci. USA 100, 9398-9403 (2003).
15. Korotkova, E. A. et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J. Virol. 77, 12460-12465 (2003).
16. MacCallum, F. O. Hypogammaglobulinaemia in the United Kingdom, VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec. Rep. Ser. Med. Res. Counc. 310, 72-85 (1971).
17. Minor, P. D. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. (Basel) 105, 75-80 (2001).
18. Halsey, N. A. et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil and the United Kingdom. Bull. World Health Organ. 82, 3-8 (2004).
19. Bellmunt, A. et al. Evolution of poliovirus type 1 during 5.5 years of prolonged enteral replication in an immune deficient patient. Virology 265, 178-184 (1999).
20. Martin, J., Dunn, G., Hull, R., Patel, V. & Minor, P. D. Evoluation of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74, 3001-3010 (2000).
21. MacLennan, C. A. et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet (in the press).
22. Poyry, T., Stenvik, M. & Hovi, T. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl. Environ. Microbiol, 54, 371-374 (1988).
23. El Bassioni, L. et al. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am. J. Epidemiol. 158, 807-815 (2003).
24. Davies, M. et al. Poliovirus type 1 in working stocks of typed human rhinoviruses. Lancet 361, 1187-1188 (2003).
25. Mulda, M. N. et al. Genetic analysis of wild-type poliovirus importation into the Netherlands (1979-1995). J. Infect. Dis. 176, 617-624 (1997).
26. Minor P. D. Biosafety consequences of eradication of wild-type polioviruses. Lancet 358, 166-168 (2001).
27. Rieder, E. et al. Will the polio niche remain vacant? Dev. Biol. (Basel) 105, 111-122 (2001).
28. Carcares, V. M. & Sutter, R. W. Sabin monovalent oral poliovaccines: review of past experiences and their potential use after polio eradication. Clin. Infect. Dis. 33, 531-541 (2001).
29. Fine, P. E. M., Oblapenko, G. & Sutter, R. E. Polio control after certification: major issues outstanding. Bull. World Health Organ. 82, 47-52 (2004).
30. Fine, P. E. & Carneiro I. A. Transmissibility and persistence of oral poliovaccine viruses: implications for the global poliomyelitis eradication initiative. Am. J. Epidemiol. 150, 1001-1021 (1999).
31. Kojouharana, M. et al. Importation and circulation of poliovirus in Bulgaria in 2001. Bull. World Health Organ. 81, 476-481 (2003).
32. WHO Consultative Group. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bull. World Health Organ. 40, 925-945 (1969).
33. Elbert, L. B. et al. Comparative study of two vaccine strains of type 3 poliovirus (USOL-D-bac and Leon 12a1b). Acta Virol. 11, 89-99 (1967).
34. Kostrezewski, J., Kulesza, A. & Abgarowicz, A. The epidemic of type 3 poliomyelitis in Poland in 1968. Epidemiol. Rev. 24, 89-103 (1970).
35. Martin, J., Ferguson, G., Wood, D. & Minor, P. D. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology 278, 42-49 (2000).
36. Dunn, G., Begg, N. T., Cammack, N. & Minor, P. D. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J. Med. Virol. 32, 92-95 (1990).
37. Macadam, A. J. et al. Live-attenuated strains of improved stability. Dev. Biol. (Basel) 105, 179-187 (2001).
38. Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H. & Wimmer, E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA 97, 6803-6808 (2000).
39. Minor, P. D. The molecular biology of poliovaccines. J. Gen. Virol. 73, 3065-3077 (1992).
40. Minor, P. D. in Picornaviruses: Current Topics In Microbiology and Immunology Vol. 161 (ed. Racaniello, V. R.) 121-154 (Springer, 1990).
41. Cedillo-Barron, L., Foster-Cuevas, M., Belsham, G. J., Lefevre, F. & Parkhouse, R. M. Induction of a protective response in swine vaccinated with DNA encoding foot and mouth disease virus empty capsid proteins and the 3D RNA polymerase. J. Gen. Virol. 82, 1713-1724 (2001).
42. Minor, P. D. in Viral Pathogenesis (eds Nathanson, N. et al.) 555-574 (Lippincott Raven Philadelphia, New York, 1997).
43. Sabin, A. B. & Boulger, L. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1, 115-118 (1973).
44. van Wezel, A. L., van Steenis, G., van der Marel, P. & Osterhaus, A. D. M. E. Inactivated-poliovirus vaccine: current production methods and new developments. Rev. Infect. Dis. 6, S335-S340 (1984).
45. Mendelsohn, C.L., Wimmer, E., Racaniello, V.R. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56, 855-865 (1989).
46. Schmid, M. & Wimmer, E. IRES-controlled protein synthesis and genome replication of poliovirus. Arch. Virol. 9, S279-S289 (1994).